# Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

> **NCT00043134** · PHASE3 · UNKNOWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 220 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT00043134
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-05
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2010-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00043134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00043134, "Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00043134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*